Press release

OncoNOx (Copenhagen, Denmark) grants Inflamalps SA (Monthey, Switzerland) an exclusive option to license and develop its front-runner drug candidate OX1001 for the treatment of inflammatory diseases. Read More



Inflamalps is a biopharmaceutical company established in Valais, Switzerland
Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic inflammatory diseases of the eye and of the skin”
Our team comprises experienced pharmaceutical industry and biotechnology company managers with significant track record in drug development, management and financing.
Our focus is on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology